Santen Pharmaceutical Co (SZD) Stock Statistics & Valuation Metrics

Santen Pharmaceutical Co has a market cap or net worth of EUR 3.25B. The enterprise value is EUR 637.18B.

Market Cap

EUR 3.25B

Enterprise Value

EUR 637.18B

Santen Pharmaceutical Co has 322,314,150 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

322,314,150

Owned by Insiders

―

Owned by Institutions

13.78%

Santen Pharmaceutical Co’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 10.57%.

Return on Equity (ROE)

0.13

Return on Assets (ROA)

0.09

Return on Invested Capital (ROIC)

10.57%

Return on Capital Employed (ROCE)

0.13

Revenue Per Employee

73.49M

Profits Per Employee

9.42M

Employee Count

3,968

Asset Turnover

0.69

Inventory Turnover

2.02

The current PE Ratio of Santen Pharmaceutical Co is 15.00. Santen Pharmaceutical Co’s PEG ratio is 0.50.

PE Ratio

15.00

PS Ratio

1.97

PB Ratio

1.91

Price to FCF

16.35

Price to Operating Cash Flow

13.99

PEG Ratio

0.50

In the last 12 months, Santen Pharmaceutical Co had revenue of 291.62B and earned 37.37B in profits. Earnings per share was 114.04.

Revenue

291.62B

Gross Profit

160.97B

Operating Income

45.22B

Pretax Income

47.44B

Net Income

37.37B

EBITDA

67.79B

Earnings Per Share (EPS)

114.04

In the last 12 months, operating cash flow was 41.04B and capital expenditures -5.94B, giving a free cash flow of 35.10B billion.

Operating Cash Flow

41.04B

Free Cash Flow

35.10B

Free Cash Flow per Share

109.22

Santen Pharmaceutical Co pays an annual dividend of ―, resulting in a dividend yield of 1.79%

Dividend Per Share

―

Dividend Yield

1.79%

Payout Ratio

N/A

Free Cash Flow Yield

6.09%

Earnings Yield

6.71%

Beta

0.21

52-Week Price Change

21.21%

50-Day Moving Average

9.47

200-Day Moving Average

9.58

Relative Strength Index (RSI)

68.13

Average Volume (3m)

150

Santen Pharmaceutical Co upcoming earnings date is Nov 05, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 06, 2026

Next Earnings Date

Nov 05, 2026

Ex-Dividend Date

―

Santen Pharmaceutical Co as a current ratio of 2.60, with Debt / Equity ratio of 11.70%

Current Ratio

2.60

Quick Ratio

1.87

Debt to Market Cap

0.05

Net Debt to EBITDA

-0.68

Interest Coverage Ratio

22.68

In the past 12 months, Santen Pharmaceutical Co has paid 9.88B in taxes.

Income Tax

9.88B

Effective Tax Rate

0.21

Santen Pharmaceutical Co EV to EBITDA ratio is 7.80, with an EV/FCF ratio of 15.08.

EV to Sales

1.81

EV to EBITDA

7.80

EV to Free Cash Flow

15.08

EV to Operating Cash Flow

12.90

Santen Pharmaceutical Co has EUR 78.26B in cash and marketable securities with EUR 31.01B in debt, giving a net cash position of EUR 47.25B billion.

Cash & Marketable Securities

EUR 78.26B

Total Debt

EUR 31.01B

Net Cash

EUR 47.25B

Net Cash Per Share

EUR 146.60

Tangible Book Value Per Share

EUR 707.90

Gross margin is 56.10%, with operating margin of 15.67%, and net profit margin of 13.25%.

Gross Margin

56.10%

Operating Margin

15.67%

Pretax Margin

16.56%

Net Profit Margin

13.25%

EBITDA Margin

23.26%

EBIT Margin

16.89%

The average price target for Santen Pharmaceutical Co is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

-10.36%

EPS Growth Forecast

17.39%